Induction of Pathogenic Innate and Adaptive Immune Responses by Schistosome Helmi

血吸虫 Helmi 诱导致病性先天性和适应性免疫反应

基本信息

  • 批准号:
    7582384
  • 负责人:
  • 金额:
    $ 3.91万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2008
  • 资助国家:
    美国
  • 起止时间:
    2008-03-01 至 2010-02-28
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Schistosomiasis is a serious, potentially fatal parasitic disease afflicting about 200 million people primarily in Africa, South America and some parts of the Middle East and Asia. The basic pathology in schistosomiasis is a CD4 T cell-mediated granulomatous inflammatory reaction against parasite eggs, which in the case of infection with Schistosoma mansoni, primarily takes place in the liver and intestines. Both in humans, as well as in a murine model, there is marked heterogeneity in the severity of disease. However, the precise regulatory mechanisms that dictate the extent of immunopathology are poorly understood. The main objective of this proposal is to investigate the role of dendritic cells (DC) in determining disease severity in murine schistosomiasis. The specific goals of this project are 1) to determine if DC isolated from high but not low pathology mouse strains can be stimulated to become activated and produce pro- inflammatory cytokines following exposure to live schistosome worms and eggs and 2) to determine if high versus low pathology DC exposed to schistosome products preferentially drive the differentiation of CD4 T cell populations to become pathogenic Th17 or protective Th2 cells, respectively. Among several standard state of the art techniques, this project will take advantage of a novel, unique S. manson/-specific TCR transgenic mouse system. Since DC are a critical link between innate and adaptive immunity, this project will provide invaluable insight into how immunopathology develops from the initial invasion of the parasite to the pathogenic T cell-mediated formation of granulomatous lesions. Despite a highly effective drug treatment with praziquantel, re-infection with schistosomes is a common occurrence in the endemic regions of the world. Unfortunately, a vaccine for schistosomiasis has yet to be developed. The research proposed in this grant will contribute to the understanding of the basic pathogenesis of schistosomiasis and to the design of specific immunotherapies.
描述(申请人提供):血吸虫病是一种严重的、可能致命的寄生虫病,主要在非洲、南美洲和中东和亚洲的一些地区困扰着大约2亿人。血吸虫病的基本病理是CD4T细胞介导的针对寄生虫卵的肉芽肿性炎症反应,在感染曼氏血吸虫的情况下,主要发生在肝脏和肠道。无论是在人类中,还是在小鼠模型中,疾病的严重程度都存在明显的异质性。然而,决定免疫病理程度的确切调控机制却知之甚少。这项建议的主要目的是研究树突状细胞(DC)在决定小鼠血吸虫病病情严重程度中的作用。该项目的具体目标是1)确定从高病理但非低病理小鼠品系分离的DC在暴露于血吸虫活虫和虫卵后是否可以被刺激激活并产生促炎细胞因子;2)确定暴露于血吸虫产品的高病理DC和低病理DC是否优先推动CD4T细胞群体分化为致病Th17细胞或保护性Th2细胞。在几项最先进的标准技术中,该项目将利用一种新颖的、独特的S.Manson/特异性TCR转基因小鼠系统。由于DC是天然免疫和获得性免疫之间的关键纽带,该项目将为免疫病理学如何从寄生虫的最初入侵发展到致病性T细胞介导的肉芽肿性病变的形成提供宝贵的见解。尽管吡喹酮是一种非常有效的药物治疗,但在世界流行地区,再次感染血吸虫是一种常见现象。不幸的是,血吸虫病疫苗还没有开发出来。这项赠款中提出的研究将有助于了解血吸虫病的基本发病机制,并有助于设计特定的免疫疗法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mara G Shainheit其他文献

Mara G Shainheit的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Mara G Shainheit', 18)}}的其他基金

Induction of Pathogenic Innate and Adaptive Immune Responses by Schistosome Helmi
血吸虫 Helmi 诱导致病性先天性和适应性免疫反应
  • 批准号:
    7488609
  • 财政年份:
    2008
  • 资助金额:
    $ 3.91万
  • 项目类别:

相似国自然基金

Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
  • 批准号:
    2022J011295
  • 批准年份:
    2022
  • 资助金额:
    10.0 万元
  • 项目类别:
    省市级项目
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
  • 批准号:
    30801055
  • 批准年份:
    2008
  • 资助金额:
    19.0 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
  • 批准号:
    BB/Y006224/1
  • 财政年份:
    2024
  • 资助金额:
    $ 3.91万
  • 项目类别:
    Research Grant
A novel vaccine approach combining mosquito salivary antigens and viral antigens to protect against Zika, chikungunya and other arboviral infections.
一种结合蚊子唾液抗原和病毒抗原的新型疫苗方法,可预防寨卡病毒、基孔肯雅热和其他虫媒病毒感染。
  • 批准号:
    10083718
  • 财政年份:
    2023
  • 资助金额:
    $ 3.91万
  • 项目类别:
    Small Business Research Initiative
Uncovering tumor specific antigens and vulnerabilities in ETP-acute lymphoblastic leukemia
揭示 ETP-急性淋巴细胞白血病的肿瘤特异性抗原和脆弱性
  • 批准号:
    480030
  • 财政年份:
    2023
  • 资助金额:
    $ 3.91万
  • 项目类别:
    Operating Grants
Regulation of B cell responses to vaccines by long-term retention of antigens in germinal centres
通过在生发中心长期保留抗原来调节 B 细胞对疫苗的反应
  • 批准号:
    MR/X009254/1
  • 财政年份:
    2023
  • 资助金额:
    $ 3.91万
  • 项目类别:
    Research Grant
Adaptive Discrimination of Risk of Antigens in Immune Memory Dynamics
免疫记忆动态中抗原风险的适应性辨别
  • 批准号:
    22KJ1758
  • 财政年份:
    2023
  • 资助金额:
    $ 3.91万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
22-ICRAD Call 2 - Improving the diagnosis of tuberculosis in domestic ruminants through the use of new antigens and test platforms
22-ICRAD 呼吁 2 - 通过使用新抗原和测试平台改善家养反刍动物结核病的诊断
  • 批准号:
    BB/Y000927/1
  • 财政年份:
    2023
  • 资助金额:
    $ 3.91万
  • 项目类别:
    Research Grant
Protective immunity elicited by distinct polysaccharide antigens of classical and hypervirulent Klebsiella
经典和高毒力克雷伯氏菌的不同多糖抗原引发的保护性免疫
  • 批准号:
    10795212
  • 财政年份:
    2023
  • 资助金额:
    $ 3.91万
  • 项目类别:
Integrative proteome analysis to harness humoral immune response against tumor antigens
综合蛋白质组分析利用针对肿瘤抗原的体液免疫反应
  • 批准号:
    23K18249
  • 财政年份:
    2023
  • 资助金额:
    $ 3.91万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
Functionally distinct human CD4 T cell responses to novel evolutionarily selected M. tuberculosis antigens
功能独特的人类 CD4 T 细胞对新型进化选择的结核分枝杆菌抗原的反应
  • 批准号:
    10735075
  • 财政年份:
    2023
  • 资助金额:
    $ 3.91万
  • 项目类别:
Targeting T3SA proteins as protective antigens against Yersinia
将 T3SA 蛋白作为针对耶尔森氏菌的保护性抗原
  • 批准号:
    10645989
  • 财政年份:
    2023
  • 资助金额:
    $ 3.91万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了